Literature DB >> 27098633

Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma.

Laurence Feldmeyer1, Victor G Prieto1, Doina Ivan1, Priyadharsini Nagarajan1, Michael T Tetzlaff1, Jonathan L Curry1, Diana Bell1, Bryan S Moon2, Carlos A Torres-Cabala1, Phyu P Aung3.   

Abstract

Aggressive digital papillary adenocarcinoma (ADPA) is a rare and often misdiagnosed malignant tumor of the sweat glands, most commonly encountered on the extremities. Due to the relatively high metastatic potential of the tumor, aggressive surgical treatment, including amputation, is generally recommended. We present a case of a 36-year-old male with an over 10-year history of a skin lesion on the right hand in the web space between the index and the middle finger. Histologically, the lesion revealed a malignant epithelioid neoplasm with features consistent with ADPA. The lesion was treated with 5-weeks preoperative radiation (total 5000 cGy) followed by surgical resection. There was no evidence of residual disease confirmed by pathological study of re-excision specimen as well as imaging studies. This is, to the best of knowledge, the first report of complete regression of an ADPA after radiotherapy.
© 2016 by the Association of Clinical Scientists, Inc.

Entities:  

Keywords:  Aggressive digital papillary adenocarcinoma; fine needle aspiration biopsy; radiotherapy

Mesh:

Year:  2016        PMID: 27098633

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  2 in total

1.  Aggressive Digital Papillary Adenocarcinoma of the Hand Presenting as a Felon.

Authors:  Justin R Bryant; Preston Gardner; Matthew Yousif; John C Pui; Raymond T Hajjar; E Aron Haass
Journal:  Case Rep Orthop       Date:  2017-03-21

Review 2.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.